Cochrane · systematic review · CD011459
Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia
Jordan, F, Quinn, TJ, McGuinness, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
26
current version
GRADE rated
16
No studies
10
Included studies
NR
No studies 10 · 38.5%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 11.5%Moderate 9 · 34.6%High 4 · 15.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aspirin compared to placebo for prevention of dementia
Population: cognitively healthy older adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of dementia Aspirin vs placebo | RR 0.98 [0.83, 1.15] | 1 study · 19114 participants | High |
Adverse events (haemorrhage) Aspirin vs placebo | RR 1.37 [1.17, 1.6] | 1 study · 19114 participants | High |
Mortality Aspirin vs placebo | RR 1.14 [1.01, 1.28] | 1 study · 19114 participants | High |
Cognitive decline from baseline Aspirin vs placebo | no estimate extracted | NR | No studies |
Activities of daily living Aspirin vs placebo | RR 0.84 [0.7, 1.02] | 1 study · 19114 participants | High |
Health‐related quality of life Aspirin vs placebo | no estimate extracted | NR | No studies |
Other NSAIDs compared to placebo for the prevention of dementia in cognitively healthy older adults
Population: cognitively healthy older adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of Alzheimer's disease Other NSAIDs vs placebo | RR 1.91 [0.89, 4.1] | 1 study · 2125 participants | Moderate Downgraded: imprecision |
Adverse events –myocardial infarction Other NSAIDs vs placebo | RR 1.21 [0.61, 2.4] | 1 study · 2500 participants | Moderate Downgraded: imprecision |
Adverse events – stroke Other NSAIDs vs placebo | RR 1.82 [0.76, 4.37] | 1 study · 2500 participants | Moderate Downgraded: imprecision |
Mortality Other NSAIDs vs placebo | RR 1.37 [0.78, 2.43] | 1 study · 2528 participants | Moderate Downgraded: imprecision |
Incidence of mild cognitive impairment Other NSAIDs vs placebo | RR 1.28 [0.72, 2.28] | 1 study · 2072 participants | Low Downgraded: risk of bias, imprecision |
Activities of daily living Other NSAIDs vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life Other NSAIDs vs placebo | no estimate extracted | NR | No studies |
NSAIDs (celecoxib) compared to placebo for the delay of cognitive decline in older people with age‐related memory loss
Population: older people with age‐related memory loss
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of dementia NSAIDs (celecoxib) vs placebo | no estimate extracted | NR | No studies |
Adverse events – gastrointestinal NSAIDs (celecoxib) vs placebo | RR 2.66 [1.05, 6.75] | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Mortality NSAIDs (celecoxib) vs placebo | no estimate extracted | NR | No studies |
Cognitive decline from baseline across 6 domains NSAIDs (celecoxib) vs placebo | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Activities of daily living NSAIDs (celecoxib) vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life NSAIDs (celecoxib) vs placebo | no estimate extracted | NR | No studies |
NSAIDs (rofecoxib) for the prevention of dementia in people with mild cognitive impairment
Population: people with MCI
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of Alzheimer's disease | RR 1.32 [1.01, 1.72] | 1 study · 1457 participants | Moderate Downgraded: imprecision |
Adverse events – cardiovascular | RR 1.07 [0.68, 1.66] | 1 study · 1457 participants | Moderate Downgraded: imprecision |
Adverse events – gastrointestinal | RR 3.53 [1.17, 10.65] | 1 study · 1457 participants | Moderate Downgraded: imprecision |
Mortality | RR 1.62 [0.85, 3.05] | 1 study · 1457 participants | Moderate Downgraded: imprecision |
Cognitive decline from baseline | no estimate extracted | NR | No studies |
Activities of daily living | no estimate extracted | 1 study · 1457 participants | Moderate Downgraded: imprecision |
Health‐related quality of life | no estimate extracted | NR | No studies |